A Prospective, Comparative, Multicenter, Randomized Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 24 Months After Kidney Transplantation.

Trial Profile

A Prospective, Comparative, Multicenter, Randomized Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 24 Months After Kidney Transplantation.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2014

At a glance

  • Drugs Sirolimus (Primary) ; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms EPARGNE
  • Most Recent Events

    • 18 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Jan 2013 Planned end date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 10 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top